Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of ...

Royalty Pharma plc (NASDAQ:RPRX) is among the 11 Best Low Priced Growth Stocks to Buy Right Now. On February 12, Goldman ...

Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now. On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total ...

Zymeworks Inc. is rated a Buy with improved FY25 profitability, narrowed net loss by 34%, and strong liquidity with $270.6M. Read more on ZYME stock here.

Pablo Legorreta, Founder, Chairman of the Board & CEO, reported "another successful quarter of execution on our goal to be the premier capital allocator in life sciences with consistent compounding ...

Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, ef ...

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed ...

Canada-based clinical-stage biotech Zymeworks ) and Royalty Pharma today announced an agreement for $250 million in funding ...

Royalty Pharma (RPRX) announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s (RHHBY) Evrysdi for $240M upfront and up to $60M in sales-based milestones.

Royalty Pharma (NASDAQ:RPRX) is preparing to release its quarterly earnings on Wednesday, 2026-02-11. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple ...